| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of disease, bringing benefits in safety and convenience. |
| Category: | Health & biotech |
| URL: | https://www.aravax.com.au/ |
| Operational Status: | Active |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | 2014 |
| Address: | Level 9, 31 Queen St, Melbourne, Victoria, 3000 Australia |
| State: | Victoria |
| Overseas Operations: | No |
| Twitter: | |
| Facebook: | |
| Linkedin: | https://www.linkedin.com/company/aravax |
| Founders: | |
| Awards won: | |
